Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.61 |
| ▸ | MAPK11 | Q15759 | 18/20 | 0.61 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.54 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12676759 | 0.85 | MAPK11 (0.65) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL1417244 | 0.83 | MAPK14 (0.61) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL3317398 | 0.83 | NPC1 (0.67) | MAPK14MAPK11MEN1KMT2A | |
| SCHEMBL11965675 | 0.81 | MAPK14 (0.61) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL243751 | 0.81 | MAPK11 (0.70) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL241982 | 0.81 | HDAC1 (0.68) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL3183420 | 0.81 | MAPK14 (0.61) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL3523687 | 0.81 | ALDH1A1 (0.60) | MEN1KMT2A | |
| SCHEMBL13523640 | 0.80 | MAPK14 (0.60) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL23591986 | 0.80 | MAPK11 (0.60) | MAPK14MAPK11MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652044-B2 | P-38 inhibitors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | disclosed |
| US-20100004298-A1 | P-38 INHIBITORS | DONG QING | 2010-01-07 | — | — | US | disclosed |
| EP-1635824-B1 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| EP-1635824-A2 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | Novartis AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005000298-A2 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2005-01-06 | — | — | WO | disclosed |
| US-20040254236-A1 | P-38 inhibitors | NOVARTIS AG (CH) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004298-A1 | P-38 INHIBITORS | MAPK8, MAPK1, MAP3K8 | MAPK14 21/4885MAPK11 38/4885MAPK13 10/4885 |
| US-20040254236-A1 | P-38 inhibitors | MAPK8, MAP3K8, MAPK1 | MAPK14 12/4885MAPK11 41/4885MAPK13 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.